<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00092014</url>
  </required_header>
  <id_info>
    <org_study_id>0217-211</org_study_id>
    <secondary_id>2004_016</secondary_id>
    <nct_id>NCT00092014</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate and Compare Alendronate and Risedronate on Bone Mineral Density in Women With Postmenopausal Osteoporosis (MK-0217-211)</brief_title>
  <acronym>FACT</acronym>
  <official_title>A 12-Month Extension to: A Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter Study to Evaluate and Compare the Effects of Once Weekly Alendronate and Risedronate on Bone Mineral Density in Postmenopausal Women With Osteoporosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to evaluate and compare the effects of Alendronate and Risedronate to treat
      women with postmenopausal osteoporosis. The primary hypothesis for this study is that in
      postmenopausal women with osteoporosis, treatment with oral alendronate 70 mg once weekly
      will produce a mean percent increase from baseline in hip trochanter bone mineral density
      (BMD) at 12 and 24 months which is greater than that observed with oral risedronate 35 mg
      once weekly.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 1, 2002</start_date>
  <completion_date type="Actual">April 1, 2004</completion_date>
  <primary_completion_date type="Actual">April 1, 2004</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean percent change from baseline in hip trochanter bone mineral density (BMD) at 12 months</measure>
    <time_frame>Baseline and 12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean percent change from baseline in hip trochanter BMD at 24 months</measure>
    <time_frame>Baseline and 24 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean percent change from baseline in total hip, femoral neck, posteroanterior (PA) lumbar BMD at 12 months</measure>
    <time_frame>Baseline and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean percent change from baseline in total hip, femoral neck, posteroanterior (PA) lumbar BMD at 24 months</measure>
    <time_frame>Baseline and 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in biochemical markers of bone turnover at 12 months</measure>
    <time_frame>Baseline and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in biochemical markers of bone turnover at 24 months</measure>
    <time_frame>Baseline and 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent responders (&gt;=0% and &gt;=3% change from baseline in hip trochanter and lumbar spine BMD) at 12 months</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent responders ((&gt;=0% and &gt;=3% change from baseline in hip trochanter and lumbar spine BMD) at 24 months</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants who experienced one or more adverse events (AE)</measure>
    <time_frame>Up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants who discontinued study medication due to an AE</measure>
    <time_frame>Up to 24 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1053</enrollment>
  <condition>Postmenopausal Osteoporosis</condition>
  <arm_group>
    <arm_group_label>Alendronate 70 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Alendronate sodium, 70 mg, orally once weekly for up to 24 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Risendronate 35 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Risendronate, 35 mg, orally once weekly for up to 24 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alendronate</intervention_name>
    <description>Alendronate sodium, 70 mg, once weekly for up to 24 months. Medications were taken fasting which was maintained for 30 minutes postdose.</description>
    <arm_group_label>Alendronate 70 mg</arm_group_label>
    <other_name>MK-0217</other_name>
    <other_name>FOSAMAX®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Risedronate 35 mg</intervention_name>
    <description>Risendronate, 35 mg, once weekly for up to 24 months. Medications were taken fasting which was maintained for 30 minutes postdose.</description>
    <arm_group_label>Risendronate 35 mg</arm_group_label>
    <other_name>Actonel®</other_name>
    <other_name>Atelvia®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Elemental Calcium</intervention_name>
    <description>Elemental calcium at least 1,000 mg daily (diet plus supplements). Medications were taken fasting which was maintained for 30 minutes postdose.</description>
    <arm_group_label>Alendronate 70 mg</arm_group_label>
    <arm_group_label>Risendronate 35 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Vitamin D</intervention_name>
    <description>Vitamin D at least 400 international units daily (diet plus supplements). Medications were taken fasting which was maintained for 30 minutes postdose.</description>
    <arm_group_label>Alendronate 70 mg</arm_group_label>
    <arm_group_label>Risendronate 35 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Risendronate placebo</intervention_name>
    <description>Risendronate placebo was taken once weekly for up to 24 months. Medications were taken fasting which was maintained for 30 minutes postdose.</description>
    <arm_group_label>Alendronate 70 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alendronate placebo</intervention_name>
    <description>Alendronate placebo was taken once weekly for up to 24 months. Medications were taken fasting which was maintained for 30 minutes postdose.</description>
    <arm_group_label>Risendronate 35 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women with postmenopausal osteoporosis

        Exclusion Criteria:

          -  Bilateral hip replacements

          -  Esophageal abnormalities

          -  Metabolic bone disease (example - Vitamin D deficiency)

          -  Medications that would affect the breakdown or build-up of bone turnover
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <reference>
    <citation>Rosen CJ, Hochberg MC, Bonnick SL, McClung M, Miller P, Broy S, Kagan R, Chen E, Petruschke RA, Thompson DE, de Papp AE; Fosamax Actonel Comparison Trial Investigators. Treatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: a randomized double-blind study. J Bone Miner Res. 2005 Jan;20(1):141-51. Epub 2004 Sep 29.</citation>
    <PMID>15619680</PMID>
  </reference>
  <reference>
    <citation>Sebba AI, Bonnick SL, Kagan R, Thompson DE, Skalky CS, Chen E, de Papp AE; Fosamax Actonel Comparison Trial investigators. Response to therapy with once-weekly alendronate 70 mg compared to once-weekly risedronate 35 mg in the treatment of postmenopausal osteoporosis. Curr Med Res Opin. 2004 Dec;20(12):2031-41. Erratum in: Curr Med Res Opin. 2005 Feb;21(2):325.</citation>
    <PMID>15706659</PMID>
  </reference>
  <reference>
    <citation>Bonnick S, Saag KG, Kiel DP, McClung M, Hochberg M, Burnett SM, Sebba A, Kagan R, Chen E, Thompson DE, de Papp AE. Comparison of weekly treatment of postmenopausal osteoporosis with alendronate versus risedronate over two years. J Clin Endocrinol Metab. 2006 Jul;91(7):2631-7. Epub 2006 Apr 24. Erratum in: J Clin Endocrinol Metab. 2007 Aug;92(8):3032.</citation>
    <PMID>16636120</PMID>
  </reference>
  <reference>
    <citation>Burnett-Bowie SM, Saag K, Sebba A, de Papp AE, Chen E, Rosenberg E, Greenspan SL. Prediction of changes in bone mineral density in postmenopausal women treated with once-weekly bisphosphonates. J Clin Endocrinol Metab. 2009 Apr;94(4):1097-103. doi: 10.1210/jc.2008-1122. Epub 2009 Jan 13.</citation>
    <PMID>19141590</PMID>
  </reference>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 21, 2004</study_first_submitted>
  <study_first_submitted_qc>September 23, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 24, 2004</study_first_posted>
  <last_update_submitted>March 28, 2017</last_update_submitted>
  <last_update_submitted_qc>March 28, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 29, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoporosis</mesh_term>
    <mesh_term>Osteoporosis, Postmenopausal</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Alendronate</mesh_term>
    <mesh_term>Risedronate Sodium</mesh_term>
    <mesh_term>Etidronic Acid</mesh_term>
  </intervention_browse>
  <study_docs>
    <study_doc>
      <doc_type>CSR Synopsis</doc_type>
      <doc_url>http://www.merck.com/clinical-trials/policies-perspectives.html</doc_url>
    </study_doc>
  </study_docs>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

